ClinicalTrials.gg
TerminatedNCT05654870Updated Nov 12, 2024

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

A Phase 3 interventional study of Valbenazine and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Terminated at 3 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
16th of 16
8 · median 165
Started
2023
with 1 other
Phase 3
6 of 16
4 open now
Registered
9th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 16th largest by enrollment, is one of 2 that started in 2023, is one of 6 in phase 3, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • valbenazine
  • antipsychotic
  • VMAT2
  • NBI-98854
  • dopamine
  • PANSS
  • Adjunctive
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Medically confirmed diagnosis of schizophrenia
  • Participant is receiving a stable regimen of background antipsychotic medication
  • Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay
  • Participant is an outpatient with stable symptomatology
  • Participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse)

Key Exclusion Criteria:

  • Has a history of treatment resistant schizophrenia
  • Have a unstable medical condition in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
  • Prior (within 6 months of Screening) or concomitant use of any vesicular monoamine transporter 2 (VMAT2) inhibitor (that is, valbenazine, reserpine, tetrabenazine, deutetrabenazine); or a history of intolerance to VMAT2 inhibitors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Valbenazine once daily

    Drug: Valbenazine

  • Placebo comparator
    Placebo

    Placebo once daily

    Drug: Placebo

Interventions

  • Oral treatment

    Also known as: NBI-98854

  • DrugPlacebo

    Placebo matching valbenazine

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) Total Score from Baseline to Week 10

    Time frame: Baseline, Week 10

Secondary outcomes

  1. Change in Clinical Global Impression of Severity (CGI-S) Score from Baseline to Week 10

    Time frame: Baseline, Week 10

  2. Change in Personal and Social Performance (PSP) Score from Baseline to Week 10

    Time frame: Baseline, Week 10

07

Study locations

3 sites
  • Neurocrine Clinical Site
    San Jose, California 95124, United States
  • Neurocrine Clinical Site
    Coral Gables, Florida 33134, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30328, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Nov 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Jan 5, 2023
Primary completionActual
Nov 8, 2023
CompletionActual
Nov 8, 2023
Results delay requested
Nov 4, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05654870
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Jan 5, 2023
Primary completion
Nov 8, 2023
Completion
Nov 8, 2023
Last update
Nov 12, 2024

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion